Evaluation of GEMCITEST in Patients With Pancreatic Cancer and Treated by Chemotherapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03599154

Acronym

GEMCIPANC

Enrollment

100

Registered

2018-07-26

Start date

2018-01-30

Completion date

2020-11-25

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Keywords

Gemcitabine

Brief summary

Pancreatic cancer has a 5-year overall survival rate around 5%. It is the 6th most common cancer in France (11 600 new annual cases in 2012) and the 4th leading cause of cancer deaths in France and Europe. Many translational research has tried to identify biomarkers in pancreatic cancer. Only the expression of hENT1 evaluated on the tumor tissue with the mouse antibody seems really relevant by providing a predictive value of the effectiveness of gemcitabine adjuvant. In a metastatic situation, there is no predictive marker of the effectiveness of chemotherapy treatments. GemciTest(TM), studied in this study, is developed by the company Acobiom. Test based on the qRT-PCR technology that allows the establishment of a molecular signature of 10 genes that showed its interest as a biomarker in 60 patients with metastatic pancreatic adenocarcinoma treated with gemcitabine. Retrospective analysis differentiated 2 patient populations: * 22 patients with a favorable expression gene with a median survival of 14.9 months * 35 patients with an adverse expression gene with a median survival of 5.1 months Primary objective: To evaluate in patients with pancreatic cancer, treated with Gemcitabine alone or combined (nab-paclitaxel) or with Folfirinox, the prognostic value of the GemciTest(TM) test on overall survival and response to treatment. To realize this study, only one 2.5 mL blood sample is taken before starting chemotherapy. The standard practice data is then saved. 100 patients will be included.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

1. Cytologically or histologically confirmed pancreatic cancer 2. Patient seeking first-line chemotherapy for pancreatic cancer 3. Age\> 18 years 4. Presence of at least 1 measurable tumor lesion according to RECIST 1.1 criteria 5. Performance index ≤ 2 6. Patient able and willing to comply with the study procedures according to the protocol 7. Patient able to understand, sign and date informed consent 8. Affiliation to a social security scheme.

Exclusion criteria

1. Contraindication to chemotherapy 2. Anti-tumor therapy, experimental or not, recent in the last 4 weeks before the inclusion of the patient 3. Active infection requiring antibiotics within 14 days before inclusion 4. Patients unable to understand, read and / or sign informed consent 5. Persons benefiting from a protection system for adults (including tutorship and guardianship) 6. Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	average of 1 year	Overall survival is defined as survival between Day 1 of the first line of chemotherapy and death

Countries

France

Outcome results